{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T19:49:31Z","timestamp":1785700171041,"version":"3.56.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,1]]},"DOI":"10.7759\/cureus.113777","type":"journal-article","created":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T19:12:26Z","timestamp":1785697946000},"source":"Crossref","is-referenced-by-count":0,"title":["Incretin-Based Therapies Versus Bariatric and Metabolic Surgery for Obesity and Type 2 Diabetes Mellitus: A Head-to-Head Systematic Review of Glycaemic, Cardiovascular, Hepatic, Weight, and Quality-of-Life Outcomes"],"prefix":"10.7759","author":[{"given":"Omar","family":"Alsayed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Zaid","family":"Jarai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarrosh","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariam","family":"Sandal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00634-7","article-title":"Bariatric-metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial","volume":"401","author":"Verrastro O","year":"2023","unstructured":"Verrastro O, Panunzi S, Castagneto-Gissey L, et al.. Bariatric-metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial. Lancet. 2023, 401:1786-97. 10.1016\/S0140-6736(23)00634-7","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding JP","year":"2021","unstructured":"Wilding JP, Batterham RL, Calanna S, et al.. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021, 384:989-1002. 10.1056\/NEJMoa2032183","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff AM","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, et al.. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022, 387:205-16. 10.1056\/NEJMoa2206038","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1600869","article-title":"Bariatric surgery versus intensive medical therapy for diabetes - 5-year outcomes","volume":"376","author":"Schauer PR","year":"2017","unstructured":"Schauer PR, Bhatt DL, Kirwan JP, et al.. Bariatric surgery versus intensive medical therapy for diabetes - 5-year outcomes. N Engl J Med. 2017, 376:641-51. 10.1056\/NEJMoa1600869","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00075-6","article-title":"Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial","volume":"386","author":"Mingrone G","year":"2015","unstructured":"Mingrone G, Panunzi S, De Gaetano A, et al.. Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial. Lancet. 2015, 386:964-73. 10.1016\/S0140-6736(15)00075-6","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32649-0","article-title":"Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial","volume":"397","author":"Mingrone G","year":"2021","unstructured":"Mingrone G, Panunzi S, De Gaetano A, et al.. Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial. Lancet. 2021, 397:293-304. 10.1016\/S0140-6736(20)32649-0","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000005003","article-title":"Patient-reported outcomes after metabolic surgery versus medical therapy for diabetes: insights from the STAMPEDE randomized trial","volume":"274","author":"Aminian A","year":"2021","unstructured":"Aminian A, Kashyap SR, Wolski KE, et al.. Patient-reported outcomes after metabolic surgery versus medical therapy for diabetes: insights from the STAMPEDE randomized trial. Ann Surg. 2021, 274:524-32. 10.1097\/SLA.0000000000005003","journal-title":"Ann Surg"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-2046","article-title":"Health-related quality of life and health utility after metabolic\/bariatric surgery versus medical\/lifestyle intervention in individuals with type 2 diabetes and obesity: the ARMMS-T2D study","volume":"48","author":"Simonson DC","year":"2025","unstructured":"Simonson DC, Gourash WF, Arterburn DE, et al.. Health-related quality of life and health utility after metabolic\/bariatric surgery versus medical\/lifestyle intervention in individuals with type 2 diabetes and obesity: the ARMMS-T2D study. Diabetes Care. 2025, 48:537-45. 10.2337\/dc24-2046","journal-title":"Diabetes Care"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-017-2770-y","article-title":"Surgical and advanced medical therapy for the treatment of type 2 diabetes in class I obese patients: a short-term outcome","volume":"27","author":"Bhandari M","year":"2017","unstructured":"Bhandari M, Mathur W, Kumar R, Mishra A, Bhandari M. Surgical and advanced medical therapy for the treatment of type 2 diabetes in class I obese patients: a short-term outcome. Obes Surg. 2017, 27:3267-72. 10.1007\/s11695-017-2770-y","journal-title":"Obes Surg"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-0708","article-title":"Effect of surgical versus medical therapy on diabetic kidney disease over 5 years in severely obese adolescents with type 2 diabetes","volume":"43","author":"Bjornstad P","year":"2020","unstructured":"Bjornstad P, Hughan K, Kelsey MM, et al.. Effect of surgical versus medical therapy on diabetic kidney disease over 5 years in severely obese adolescents with type 2 diabetes. Diabetes Care. 2020, 43:187-95. 10.2337\/dc19-0708","journal-title":"Diabetes Care"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-026-08508-5","article-title":"Efficacy of metabolic and bariatric surgery compared with GLP-1 receptor agonist treatment in preventing mortality and major adverse cardiac events among individuals with obesity and type 2 diabetes: a systematic review and meta-analysis","volume":"36","author":"Chadwick J","year":"2026","unstructured":"Chadwick J, Sivamani C, Lakshmi S, et al.. Efficacy of metabolic and bariatric surgery compared with GLP-1 receptor agonist treatment in preventing mortality and major adverse cardiac events among individuals with obesity and type 2 diabetes: a systematic review and meta-analysis. Obes Surg. 2026, 36:1377-88. 10.1007\/s11695-026-08508-5","journal-title":"Obes Surg"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/s41366-023-01254-z","article-title":"Major adverse cardiovascular events among patients with type-2 diabetes, a nationwide cohort study comparing primary metabolic and bariatric surgery to GLP-1 receptor agonist treatment","volume":"47","author":"Stenberg E","year":"2023","unstructured":"Stenberg E, N\u00e4slund E. Major adverse cardiovascular events among patients with type-2 diabetes, a nationwide cohort study comparing primary metabolic and bariatric surgery to GLP-1 receptor agonist treatment. Int J Obes (Lond). 2023, 47:251-6. 10.1038\/s41366-023-01254-z","journal-title":"Int J Obes (Lond)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1093\/bjs\/znae221","article-title":"Cardiovascular and diabetes outcomes among patients with obesity and type 2 diabetes after metabolic bariatric surgery or glucagon-like peptide 1 receptor agonist treatment","volume":"111","author":"Stenberg E","year":"2024","unstructured":"Stenberg E, Ottosson J, Cao Y, Sundbom M, N\u00e4slund E. Cardiovascular and diabetes outcomes among patients with obesity and type 2 diabetes after metabolic bariatric surgery or glucagon-like peptide 1 receptor agonist treatment. Br J Surg. 2024, 111:221. 10.1093\/bjs\/znae221","journal-title":"Br J Surg"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.15392","article-title":"Bariatric metabolic surgery vs glucagon-like peptide-1 receptor agonists and mortality","volume":"7","author":"Dicker D","year":"2024","unstructured":"Dicker D, Sagy YW, Ramot N, et al.. Bariatric metabolic surgery vs glucagon-like peptide-1 receptor agonists and mortality. JAMA Netw Open. 2024, 7:e2415392. 10.1001\/jamanetworkopen.2024.15392","journal-title":"JAMA Netw Open"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso SP","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, et al.. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016, 375:311-22. 10.1056\/NEJMoa1603827","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso SP","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, et al.. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016, 375:1834-44. 10.1056\/NEJMoa1607141","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome PN","year":"2021","unstructured":"Newsome PN, Buchholtz K, Cusi K, et al.. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021, 384:1113-24. 10.1056\/NEJMoa2028395","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.89409","article-title":"Long-term efficacy of bariatric surgery compared to modern medical therapy in type 2 diabetes and obesity: a systematic review","volume":"17","author":"Afzal A","year":"2025","unstructured":"Afzal A, Pandey JR, Ashraf T, et al.. Long-term efficacy of bariatric surgery compared to modern medical therapy in type 2 diabetes and obesity: a systematic review. Cureus. 2025, 17:e89409. 10.7759\/cureus.89409","journal-title":"Cureus"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/516517-incretin-based-therapies-versus-bariatric-and-metabolic-surgery-for-obesity-and-type-2-diabetes-mellitus-a-head-to-head-systematic-review-of-glycaemic-cardiovascular-hepatic-weight-and-quality-of-life-outcomes","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T19:12:26Z","timestamp":1785697946000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/516517-incretin-based-therapies-versus-bariatric-and-metabolic-surgery-for-obesity-and-type-2-diabetes-mellitus-a-head-to-head-systematic-review-of-glycaemic-cardiovascular-hepatic-weight-and-quality-of-life-outcomes"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.113777","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,1]]}}}